new oral glp 1 agonist The challenge of developing alternatives to Ozempic, Wegovy and Mounjaro A new oral GLP-1 medication

Compounding is a practice in which pharmacy companies can make and sell a drugoften at a lower costfor patients with specific medical needs

A few highlights: Accelerated eGFR decline during the year preceding a heart failure event Slower decline afterward but still exacerbated A parallel between eGFR slope and NYHA class, suggesting the kidney may be signaling congestion early These findings call for a shift in practice: instead of relying on static eGFR thresholds, tracking its trajectory over time could help us identify at-risk patients sooner and intervene before hospitalization

These agents reduce hepatic de novo lipogenesis in vivo, with a reported 1.26% decrease compared to a 1.30% increase observed with placebo

The long-term weight-loss agents approved by the FDA of the United States are orlistat, lorcaserin, naltrexone-bupropion, topiramate phenylacetate, LIR, SMG etc

C., Kashkouli, A

Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement